sars-cov-2

SARS-CoV-2-IN-38 is an orally available SARS-CoV-2 inhibitor with potential antiviral activity for the study of SARS viral infections.

SARS-CoV-2 Mpro-IN-9 (compound c7), a nonpeptidic, noncovalent inhibitor of SARS-CoV-2 main protease (Mpro), exhibits potent inhibitory action (IC50 = 0.085 μM) and improved physicochemical and drug metabolism and pharmacokinetics (DMPK) properties. It effectively suppresses viral replication in SARS-CoV-2-infected Vero E6 cells (EC50 = 1.10 μM) and demonstrates low cytotoxicity (CC50 > 50 μM) [1].

SARS-CoV-2-IN-39 is a SARS-CoV-2 inhibitor with an EC50 of 1 μM. SARS-CoV-2-IN-39 has antiviral activity and inhibits SARS-CoV-2 by inhibiting SKP2 protein and stabilizing BECN1.

SARS-CoV-2-IN-13 (compound 5) is an analogue of niclosamide, displaying greater stability in human plasma and liver S9 enzymes assay. It improves bioavailability and half-life when administered orally and is a potent SARS-CoV-2 inhibitor with an IC50 of 0.057 μM [1].

SARS-CoV-2-IN-46, a SARS-CoV-2 inhibitor, is [2-({[(5-nitrofuran-2-yl)methylidene]amino}oxy)-N-(pyrimidin-2-yl)acetamide].

VV116 is a selective and orally active nucleoside antiviral agent against respiratory syncytial virus and SARS-CoV-2 infection.[1]

Chloroquine is a Toll-like receptor inhibitor that inhibits autophagy. Chloroquine has anti-malarial and anti-inflammatory activity and is widely used in the treatment of malaria and rheumatoid arthritis. Chloroquine also has anti-SARS-CoV-2 (COVID-19) activity and anti-HIV-1 activity.

Theodrenaline hydrochloride is an inhibitor targeting SARS-CoV-2 for the study of hypotension induced by spinal anesthesia.

ONO-5334 is a selective, orally active and potent histone K inhibitor with anti-SAR-COV-2 and anti-bone resorption activity for the study of osteoporosis.

Setrobuvir (ANA-598) is an orally active, highly selective non-nucleoside HCV NS5B polymerase inhibitor that inhibits new RNA synthesis and primer extension, with IC₅₀ values ranging from 4 to 5 nM. Setrobuvir exhibits high binding affinity for SARS-CoV-2 RdRp and induces inhibition of RdRp. Setrobuvir is suitable for Antiviral drugs studies.

Sonedenoson (MRE0094) is an adenosine A(2A) receptor agonist and potential inhibitor potentially targeting SARS-CoV-2 coronavirus 2;-O-ribose methyltransferase, and may be used in the study of diabetic foot ulcers.

Leritrelvir (RAY1216) is an orally active and highly potent protease inhibitor with antiviral activity that blocks cleavage of viral precursor proteins and inhibits viral replication in SARS-CoV-2.

Umifenovir is a potent, orally active broad-spectrum antiviral agent with activity against enveloped and non-enveloped viruses, suppressing virus propagation and modulating the expression of inflammatory cytokines for use as an anti-influenza virus agent [3]. It effectively inhibits the fusion of the virus with host cells [1] [2] and is an efficient inhibitor of SARS-CoV-2 in vitro [2].

(Rac)-X77 (MUN91789) is a potent SARS- CoV- 2 main protease inhibitor.

Ivermectin B1a is the major (80%) component of commercially available ivermectin and a derivative of Avermectin B1a.

Bisoxatin (LA 271A) is an oral laxative that can be used to study contact laxatives for chronic constipation.

GS-621763, a prodrug of GS-441524, exhibits antiviral activity against SARS-CoV-2 pathogenesis.

CCF0058981 (CCF981) is a 3-chlorophenyl analogue, serving as a noncovalent inhibitor of SARS-CoV-2 3CL pro (SC2), demonstrating potent activity with an IC50 of 68 nM. It also exhibits inhibitory effects against SARS-CoV-1 3CL pro (SC1) with an IC50 of 19 nM, highlighting its antiviral efficacy and potential in COVID-19 research [1].

Bismuth Subcitrate Potassium is an antibiotic that acts against 12 species of Helicobacter pylori, inhibits the histamine H2 receptor, and can be used to study diarrhea and peptic ulcer disease in vulnerable patients with SARS-CoV-2 infections.

EIDD-2749 (4'-FlU), a ribonucleoside analog, is an orally available RdRp inhibitor with spectroscopic antiviral activity that interrupts the replication of respiratory syncytial virus and SARS-CoV-2.EIDD-2749 attenuates lethal infections of pandemic human and highly pathogenic avian influenza viruses.

Merafloxacin (CI 934) is a fluoroquinolone antibacterial, which was also identified as a 1 PRF inhibitor of SARS-CoV-2.

Bemnifosbuvir hemisulfate (AT-527) is a potent inhibitor of HCV virus replication.

PF-00835231 is a CoV-2 cysteine 3C-like protease (3CLpro) inhibitor, with IC50s of 0.27 nM and 4 nM for SARS CoV-2 and SARS CoV-1 3CLpro, respectively. PF-00835231 is the active compound of the first anti-3CLpro regimen in clinical trials.

RdRP-IN-2 is an RNA-dependent RNA polymerase (RdRp) inhibitor that significantly inhibits SARS-CoV-2 RdRp with an IC50 of 41.2 µM and also inhibits Feline coronavirus (FIPV) replication.